| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$67.3M | ROE | −32.99% |
| Net Margin | — | ROIC | −18.44% |
| Debt / Equity | 0.53 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Geron is a commercial-stage biopharmaceutical company focused on developing therapeutics for oncology. Its lead product, RYTELO, is a telomerase inhibitor for adults with lower-risk myelodysplastic syndromes and transfusion-dependent anemia. Its pipeline includes IMerge and IMpactMF in Phase 3, Impress in Phase 2, IMproveMF in Phase 1, and IMAGINE in Phase 1/2, addressing myelodysplastic syndromes, myelofibrosis, and acute myeloid leukemia.
| Market Cap | $898.1M | Trading Days | 5293 |
| 52W High | 2.01 |
| 52W Low | 1.04 |
| % Off High | −30.35% |
| YTD | 6.06% | 1Y | 22.81% |
| 3Y | −56.79% | 5Y | 13.82% |
| 10Y | −47.76% | Since incept. (ann.) | −8.04% |
Reportable 100%
| Ann. Volatility (1Y) | 61.77% | Ann. Volatility (3Y) | 84.39% |
| Sharpe (1Y) | 0.63 | Sharpe (3Y) | 0.04 |
| Max Drawdown (1Y) | −42.05% | Max Drawdown (3Y) | −78.98% |
| Beta (3Y, vs SPY) | 0.90 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc. | $907.4M | 10.1 |
| JANX | Janux Therapeutics, Inc. | $912.3M | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $928.4M | — |
| TBPH | Theravance Biopharma, Inc. | $868.7M | 8.2 |
| VYNE | VYNE Therapeutics Inc. | $935.5M | — |
| ANRO | Alto Neuroscience, Inc. | $937.7M | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $951.3M | — |
| ABUS | Arbutus Biopharma Corp | $847.4M | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $952.3M | — |
| OMER | OMEROS CORP | $844.6M | — |
| JBIO | Jade Biosciences, Inc. |
| $955.1M |
| — |
| CMMB | Chemomab Therapeutics Ltd. | $840.1M | 81.1 |